We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

131 hedge funds and large institutions have $125M invested in ImmunityBio in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 33

0.63% less ownership

Funds ownership: 8.95% → 8.32% (-0.63%)

5% less call options, than puts

Call options by funds: $1.99M | Put options by funds: $2.08M

12% less funds holding

Funds holding: 149 → 131 (-18)

37% less capital invested

Capital invested by funds: $200M → $125M (-$74.4M)

45% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 31

Holders
131
Holders Change
-18
Holders Change %
-12.08%
% of All Funds
2.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
54
Reduced
33
Closed
31
Calls
$1.99M
Puts
$2.08M
Net Calls
-$95K
Net Calls Change
+$1.83M

Top Buyers

1
BlackRock
BlackRock
New York
+$3.19M
2
Millennium Management
Millennium Management
New York
+$2.29M
3
Citadel Advisors
Citadel Advisors
Florida
+$1.76M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.61M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.47M

Top Sellers

1
State Street
State Street
Massachusetts
-$19.6M
2
OIM
Oracle Investment Management
Connecticut
-$2.24M
3
Rafferty Asset Management
Rafferty Asset Management
New York
-$1.99M
4
Marshall Wace
Marshall Wace
United Kingdom
-$861K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$764K
Name Holding Trade Value Shares
Change 		Change in
Stake
OIM
126
Oracle Investment Management
Connecticut
– -$2.24M -400,013 Closed
Marshall Wace
127
Marshall Wace
United Kingdom
– -$861K -153,282 Closed
Allspring Global Investments
128
Allspring Global Investments
North Carolina
– -$701K -124,998 Closed
ASN
129
Advisory Services Network
Georgia
– -$636K -113,299 Closed
Los Angeles Capital Management
130
Los Angeles Capital Management
California
– -$359K -64,030 Closed
Mitsubishi UFJ Asset Management
131
Mitsubishi UFJ Asset Management
Japan
– -$260K -46,433 Closed
TSS
132
Two Sigma Securities
New York
– -$227K -40,502 Closed
Handelsbanken Fonder
133
Handelsbanken Fonder
Sweden
– -$151K -26,900 Closed
Wolverine Trading
134
Wolverine Trading
Illinois
– -$105K -26,082 Closed
EFM
135
E Fund Management
China
– -$128K -22,816 Closed
JF
136
Jump Financial
Illinois
– -$123K -21,900 Closed
EGM
137
Engineers Gate Manager
New York
– -$114K -20,292 Closed
BAM
138
Berkshire Asset Management
Pennsylvania
– -$84K -15,000 Closed
VF
139
Virtu Financial
New York
– -$74K -13,190 Closed
Commonwealth Equity Services
140
Commonwealth Equity Services
Massachusetts
– -$73K -13,108 Closed
TI
141
Tidal Investments
Wisconsin
– -$63K -11,219 Closed
AW
142
Alaethes Wealth
Nevada
– -$29K -5,175 Closed
Federated Hermes
143
Federated Hermes
Pennsylvania
– -$11K -1,998 Closed
Nisa Investment Advisors
144
Nisa Investment Advisors
Missouri
– -$9K -1,600 Closed
PFS
145
Prospera Financial Services
Texas
– -$9K -1,559 Closed
LC
146
Lindbrook Capital
California
– -$6K -1,000 Closed
ACM
147
Aquatic Capital Management
Illinois
– -$2K -400 Closed
MCM
148
Manchester Capital Management
Vermont
– -$1K -264 Closed
CWP
149
Concord Wealth Partners
Virginia
– -$1K -173 Closed
Koshinski Asset Management
150
Koshinski Asset Management
Illinois
– -$230 -41 Closed
3 4 5
6
7

IBRX Hedge Fund Activity: Q2 2022 in Review

131 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2022, worth a combined $125M — down 37% from $200M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of IBRX and 17 opened new positions — a net loss of 14 holders — while 33 trimmed existing stakes and 54 added.

The largest buyer was BlackRock, adding an estimated $3.19M. The largest seller was State Street, cutting an estimated $19.6M.

  • 131 institutional investors held ImmunityBio (IBRX) as of Q2 2022, down from 149 in Q1 2022.
  • Funds reported $125M of ImmunityBio stock for Q2 2022, down 37% quarter-over-quarter.
  • 17 funds opened new ImmunityBio positions in Q2 2022 and 31 closed out, a net change of -14 holders.
  • The largest ImmunityBio buyer in Q2 2022 was BlackRock, an estimated $3.19M added.
  • The largest ImmunityBio seller in Q2 2022 was State Street, an estimated $19.6M sold.

Based on aggregated 13F filings for Q2 2022.